CLAIMS

1. Crystalline solid salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), wherein the salts are selected from the group consisting of:

N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1) • pyruvate, wherein the crystalline solid comprises Compound 1 and pyruvate in a 1:1 molar ratio;

N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1) • glutarate, wherein the crystalline solid comprises Compound 1 and glutarate in a 1:1 molar ratio;

and

N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1) • isethionate monohydrate, wherein the crystalline solid comprises Compound 1 and isethionate in a 1:1 molar ratio.

2. Crystalline solid Compound 1 • pyruvate, characterized as Form 14, according to claim 1, wherein the Form 14 is characterized by one or more peaks in an XRPD pattern selected from the group consisting of 7.84, 8.81, 11.58, 15.67, 16.30, 16.55, 17.67, 17.92, 18.00, 18.20, 18.62, 19.66, 20.54, 20.75, 23.84, 26.35, and 26.42 degrees on a 2-theta scale.

3. Crystalline solid Compound 1 • pyruvate, characterized as Form 14, according to claim 1 or claim 2, wherein the Form 14 is characterized by the peaks at 8.81, 11.58, 17.67, 18.00, 23.84, and 26.35 degrees on a 2-theta scale in an X-ray powder diffraction spectrum.

4. Crystalline solid Compound 1 • pyruvate, characterized as Form 14, according to any one of claims 1-3, wherein the Form 14 is characterized by an XRPD pattern according to FIG. 5.

5. Crystalline solid Compound 1 • pyruvate, characterized as Form 14, according to claim 1, wherein the Form 14 is characterized by a thermal event with peak temperature at about 183 °C in a differential scanning calorimetry (DSC) thermogram recorded at 10 °C/min.

6. Crystalline solid Compound 1 • pyruvate, characterized as Form 14, according to claim 1, wherein the Form 14 is characterized by a broad endotherm at an onset temperature of about 157 °C, with an associated weight loss of about 11.4% as measured by thermogravimetric differential Thermal analysis (TG/DTA).

7. Crystalline solid Compound 1 • pyruvate, characterized as Form 14, according to claim 1, wherein the Form 14 is characterized by a total weight gain between 0% relative humidity and 80% relative humidity of about 0.10% w/w, as measured by dynamic vapor sorption (DVS).

8. Crystalline solid Compound 1 • glutarate, characterized as Form 20, according to claim 1, wherein the Form 20 is characterized by one or more peaks in an X-ray powder diffraction spectrum selected from the group consisting of 8.06, 11.77, 19.97, 20.21, 22.27, 23.11, 23.17, 25.81, 25.87, 26.00, and 26.06 degrees on a 2-theta scale.

9. Crystalline solid Compound 1 • glutarate, characterized as Form 20, according to claim 1 or claim 8, wherein the Form 20 is characterized by the peaks at 8.06, 11.77, 20.21, 22.27, 23.11, 25.81, 25.87, and 26.00 degrees on a 2-theta scale in an X-ray powder diffraction spectrum.

10. Crystalline solid Compound 1 • glutarate, characterized as Form 20, according to any one of claims 1 or 8-9, wherein the Form 20 is characterized by an XRPD pattern according to FIG. 7.

11. Crystalline solid Compound 1 • glutarate, characterized as Form 20, according to claim 1, wherein the Form 20 is characterized by a thermal event with peak temperature at about 176 °C in a differential scanning calorimetry (DSC) thermogram recorded at 10 °C/min

12. Crystalline solid Compound 1 • glutarate, characterized as Form 20, according to claim 1, wherein the Form 20 is characterized by an endotherm at an onset temperature of about 175 °C, with an associated weight loss of about 0.5% as measured by thermogravimetric differential

Thermal analysis (TG/DTA).

13. Crystalline solid Compound 1 • glutarate, characterized as Form 20, according to claim 1, wherein the Form 20 is characterized by a total weight gain between 0% relative humidity and 80% relative humidity of about 0.08% w/w, as measured by dynamic vapor sorption (DVS).

14. Crystalline solid Compound 1 • isethionate monohydrate, characterized as Form 27, according to claim 1, wherein the Form 27 is characterized by one or more peaks in an X-ray powder diffraction spectrum selected from the group consisting of 6.56, 12.39, 12.59, 13.14, 16.57, 17.55, 21.68, 23.66, 24.33, 26.09, 26.53, 26.69, and 27.40 degrees on a 2-theta scale.

15. Crystalline solid Compound 1 • isethionate monohydrate, characterized as Form 27, according to claim 1 or claim 14, wherein the Form 27 is characterized by the peaks at 12.39, 12.59, 17.55, 21.68, 23.66, 24.33, and 26.09 degrees on a 2-theta scale in an X-ray powder diffraction spectrum.

16. Crystalline solid Compound 1 • isethionate monohydrate, characterized as Form 27, according to any one of claims 1 or 14-15, wherein the Form 27 is characterized by an XRPD pattern according to FIG. 9.

17. Crystalline solid Compound 1 • isethionate monohydrate, characterized as Form 27, according to claim 1, wherein the Form 27 is characterized by a first thermal event with a peak temperature at about 80 °C and a second thermal event with a peak temperature at about 203 °C in a differential scanning calorimetry (DSC) thermogram recorded at 10 °C/min.

18. Crystalline solid Compound 1 • isethionate monohydrate, characterized as Form 27, according to claim 1, wherein the Form 27 is characterized by a first endotherm at an onset temperature of about 49 °C, with an associated weight loss of about 3%, and a second endotherm at an onset temperature of about 196 °C, with no associated weight loss as measured by thermogravimetric differential Thermal analysis (TG/DTA).

19. Crystalline solid Compound 1 • isethionate monohydrate, characterized as Form 27, according to claim 1, wherein the Form 27 is characterized by a total weight gain between 20% relative humidity and 80% relative humidity of about 2.4% w/w, as measured by dynamic vapor sorption (DVS).

20. A pharmaceutical composition comprising a therapeutically effective amount of a substantially pure crystalline solid form of a salt of Compound 1 as recited by any one of claims 1-19 and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising a therapeutically effective amount of a mixture of crystalline solid forms of a salt of Compound 1 as recited by any one of claims 1-19 and a pharmaceutically acceptable carrier.

22. A crystalline solid form of a salt of Compound 1 as recited by any one of claims 1-19 for use in the treatment of cancer.

23. A pharmaceutical composition as recited by any one of claims 20-21 for use in the treatment of cancer.

24. The crystalline solid form for use of claim 22 or the pharmaceutical composition for use of claim 23, wherein the cancer is selected from thyroid cancer, stomach cancer, esophageal carcinoma, kidney cancer, liver cancer, ovarian carcinoma, cervical carcinoma, bladder cancer, large bowel cancer, small bowel cancer, brain cancer, lung cancer, bone cancer, prostate carcinoma, pancreatic carcinoma, skin cancer, bone cancer, lymphoma, solid tumors, Hodgkin's disease, or non-Hodgkin's lymphoma.

25. The crystalline solid form for use or the pharmaceutical composition for use of claim 24, wherein the thyroid cancer is medullary thyroid cancer.

26. The crystalline solid form for use or the pharmaceutical composition for use of claim 24, wherein the kidney cancer is renal cell carcinoma.

27. The crystalline solid form for use or the pharmaceutical composition for use of claim 24, wherein the liver cancer is hepatocellular carcinoma.

28. The crystalline solid form for use or the pharmaceutical composition for use of claim 24, wherein the brain cancer is an astrocytic tumor.

29. The crystalline solid form for use or the pharmaceutical composition for use of claim 28, wherein the astrocytic tumor is selected from a glioblastoma, a giant cell glioblastoma, and a gliosarcoma.

30. The crystalline solid form for use or the pharmaceutical composition for use of claim 29, wherein the glioblastoma possesses oligodendroglial components.

31. The crystalline solid form for use or the pharmaceutical composition for use of claim 24, wherein the lung cancer is non-small cell lung cancer.

32. The crystalline solid form for use or the pharmaceutical composition for use of claim 24, wherein the prostate carcinoma is castration resistant prostate cancer.

33. Use of a crystalline solid form of a salt of Compound 1 as recited by any one of claims 1-19 for the manufacture of a medicament for treating cancer.

34. The use of claim 33, wherein the cancer is selected from thyroid cancer, stomach cancer, esophageal carcinoma, kidney cancer, liver cancer, ovarian carcinoma, cervical carcinoma, bladder cancer, large bowel cancer, small bowel cancer, brain cancer, lung cancer, bone cancer, prostate carcinoma, pancreatic carcinoma, skin cancer, bone cancer, lymphoma, solid tumors, Hodgkin’s disease, or non-Hodgkin’s lymphoma.